Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Agomab Therapeutics Completes Acquisition of Origo Biopharma

Thursday, December 16, 2021

Agomab Therapeutics NV (‘Agomab’) announced today the closing of the Origo Biopharma acquisition. The transaction, first announced on October 28th, 2021, combines Spanish biotech Origo Biopharma and its pipeline of organ-restricted small molecule drug candidates targeting the transforming growth factor beta (TGF-β) pathway with Agomab’s hepatocyte growth factor (HGF)-targeting programs. The merged company will focus on developing therapeutics that translate growth factor signaling pathways into innovative therapies for the treatment of fibrosis related diseases.

“Through this acquisition, we have taken a big step in broadening our clinical-stage pipeline and are ultimately one step closer to bringing meaningful treatments to patients with fibrotic diseases. The synergies between Origo’s unique small molecule platform and Agomab’s antibody capabilities, combined with our collective expertise in targeting growth factors, will allow us to accelerate the development of novel therapeutic candidates,” said Paul van der Horst, Chief Business Officer at Agomab Therapeutics. “We would like to thank all the parties who have supported the completion of this transaction.”

Agomab will integrate the full Origo team as well as its facilities in Touro and Barcelona in Spain into its current organization, complementing Agomab’s headquarters in Belgium and research laboratories in Italy.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024